Effects of hepatic portal infusion of hypertonic saline on glucagon response to exercise.
The present study was conducted to evaluate the influence of a hepatic portal infusion of hypertonic saline on the metabolic and hormonal responses to exercise. Adrenodemedullated male rats were studied at rest or after 30 min of treadmill exercise (26 m/min, 0% grade). Three groups of rats were infused continuously at a rate of 52 microL/min with one of the following randomly assigned conditions: hypertonic 3.6% NaCl (P3.6% NaCl) or 1.8% NaCl (P1.8% NaCl) infused into the hepatic portal vein, and hypertonic 3.6% NaCl (J3.6% NaCl) infused into the jugular vein. One group of rats received no infusion (SHAM). The infusions of hypertonic NaCl into the portal or the jugular site resulted in a significant (p < 0.05) increase in peripheral concentration of Na+, Cl-, and osmolality at rest and after exercise. The antidiuretic hormone (ADH) concentration was significantly (p < 0.05) increased by the P3.6% NaCl and J3.6% NaCl infusions at rest and after exercise. Exercise caused a significant (p < 0.05). decrease in liver glycogen content, peripheral and portal plasma glycemia, and insulinemia regardless of the different types and sites of infusions. However, the peripheral glucagon response to exercise was significantly (p < 0.05) increased only when hypertonic saline (1.8 or 3.6%) was infused into the portal vein. Portal and peripheral lactate concentrations at rest and after exercise were significantly (p < 0.01) higher in P3.6% NaCl than in all other groups. It is concluded that a 30-min hypertonic saline infusion into the hepatic portal vein does not specifically influence the insulin response at rest and after exercise, but that glucagon response to exercise is increased by such an infusion.
Latour
M G
MG
Department of Kinesiology, Université de Montréal, Québec, Canada.
Bergeron
R
R
Lavoie
J M
JM
D000313:Adrenal Medulla / Q000187:drug effects / Q000502:physiology; D000315:Adrenalectomy; D000704:Analysis of Variance; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D002628:Chemoreceptor Cells / Q000187:drug effects* / Q000502:physiology; D005934:Glucagon / Q000097:blood; D007262:Infusions, Intravenous; D007328:Insulin / Q000097:blood; D007601:Jugular Veins; D008099:Liver / Q000187:drug effects* / Q000502:physiology; D008297:Male; D009994:Osmolar Concentration; D010179:Pancreas / Q000187:drug effects* / Q000502:physiology; D010805:Physical Conditioning, Animal / Q000502:physiology; D011169:Portal Vein; D051381:Rats; D017207:Rats, Sprague-Dawley; D012462:Saline Solution, Hypertonic / Q000494:pharmacology*
D001786:Blood Glucose; D007328:Insulin; D012462:Saline Solution, Hypertonic; D005934:Glucagon